Tag Archive for: Cancer

Adcendo ApS and Multitude Therapeutics Inc. Announce Global Development and Commercialization Agreement on First-in-class ADC Drug Candidate Targeting Tissue Factor

/in

August 20th, 2024, Copenhagen, Denmark and Shanghai, China — Adcendo ApS (“Adcendo”) and Multitude Therapeutics Inc. (“Multitude”) jointly announced today that they have signed a licensing agreement for the development of a novel, highly differentiated antibody-drug conjugate (ADC) targeting Tissue Factor (TF) with the development code ADCE-T02. Under this agreement, Adcendo will obtain the exclusive development and commercialization […]

Read more

iOnctura announces expansion of roginolisib clinical trial program to NSCLC

/in

• Phase II study in non-small-cell-lung-cancer (NSCLC) to be run in collaboration with the ETOP IBCSG Partners Foundation across sites in Europe • Study will investigate dostarlimab + roginolisib +/- docetaxel in patients with NSCLC resistant to first-line checkpoint inhibitor therapy Geneva, Switzerland and Amsterdam, The Netherlands, 9 July 2024 – iOnctura, a clinical-stage biopharmaceutical […]

Read more

Death cap poison: the latest weapon in the fight against cancer

/in

The death cap mushroom is feared throughout much of the world because of the deadly toxin it contains, amanitin. But could the poison reputedly used by Agrippina to murder her husband, the Roman emperor Claudius, be used to destroy cancer, asks Richard Staines. Known to modern science as an inhibitor of RNA polymerase II, alpha-Amanitin […]

Read more

iOnctura announces EUR80 million Series B financing to progress pipeline through Phase II trials

/in

• Led by new investor Syncona, with participation from the European Innovation Council Fund as well as existing investors • To progress pipeline of innovative, first-in-class, oral cancer treatments targeting neglected and hard-to-treat cancers • To accelerate development of lead asset roginolisib for treatment of uveal melanoma and a number of other oncology indications Geneva, […]

Read more

Tony Kouzarides, Founder of STORM Therapeutics, Awarded British Knighthood for Services to Healthcare Innovation and Delivery

/in

Ground-breaking discoveries on the characteristics of RNA epigenetics unveiled novel targets to treat diseases 17 June 2024, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, is delighted to announce that its Founder & Director and Professor of Cancer Biology, University of Cambridge, UK, Tony Kouzarides, […]

Read more
© Optimum Strategic Communications.